<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38984895</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1941-837X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Journal of medical economics</Title><ISOAbbreviation>J Med Econ</ISOAbbreviation></Journal><ArticleTitle>Impact of COVID-19 on work loss in the United States- A retrospective database analysis.</ArticleTitle><Pagination><StartPage>941</StartPage><EndPage>951</EndPage><MedlinePgn>941-951</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13696998.2024.2379056</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">This study investigates the utilization of work absence benefits among United States (US) employees diagnosed with COVID-19, examining frequency, duration, cost, and types of work loss benefits used.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This retrospective analysis of the Workpartners Research Reference Database (RRDb) included employees eligible for short- and long-term disability (STD and LTD employer-sponsored benefits, respectively), and other paid work absence benefits from 2018 to 2022. Workpartners RRDb includes over 3.5 million employees from over 500 self-insured employers across the US. Employees were identified by codes from adjudicated medical and disability claims for COVID-19 (2020-2022) and influenza, as well as prescription claims for COVID-19 treatments. Associated payments were quantified for each absence reason.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Approximately 1 million employees were eligible for employer-sponsored paid leave benefits between January 2018 and December 2022. The mean age was 37&#x2009;years (22% &gt;50&#x2009;years), and 49.4% were females. COVID-19 was the 2nd most common reason for an STD claim (6.9% of all STD claims) and 13th for an LTD claim (1.7% of all LTD claims) from 2020-2022. The mean duration for COVID-19 STD claims was 24&#x2009;days (<i>N</i>&#x2009;=&#x2009;3,731, mean claim=$3,477) versus 10&#x2009;days for influenza (<i>N</i>&#x2009;=&#x2009;283, mean claim=$1,721). The mean duration for an LTD claim for COVID-19 was 153&#x2009;days (<i>N</i>&#x2009;=&#x2009;11, mean claim=$19,254). Only 21.5% of employees with STD claims in the COVID-19 cohort had prior COVID-19-associated medical or pharmacy claims; over half (range 53%-61%) had documented high risk factors for severe COVID-19.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">COVID-19 and influenza have the potential to cause work loss in otherwise healthy employees. In this analysis, COVID-19 was the second most frequent reason for an STD claim at the start of the pandemic and remained high (ranked 5th) in 2022. These results highlight the impact of COVID-19 on work loss beyond the acute phase. Comprehensively evaluating work loss implications may help employers prioritize strategies, such as vaccinations and timely treatments, to mitigate the impact of COVID-19 on employees and their companies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Judy</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2246-9745</Identifier><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yehoshua</LastName><ForeName>Alon</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0009-2920-916X</Identifier><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gouveia-Pisano</LastName><ForeName>Julie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1550-4749</Identifier><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brook</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-6277-9705</Identifier><AffiliationInfo><Affiliation>Better Health Worldwide, Newfoundland, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinman</LastName><ForeName>Nathan L</ForeName><Initials>NL</Initials><Identifier Source="ORCID">0000-0001-5779-3679</Identifier><AffiliationInfo><Affiliation>Better Health Worldwide, Newfoundland, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drnach</LastName><ForeName>Alek A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0009-0003-7810-1944</Identifier><AffiliationInfo><Affiliation>Workpartners, LLC, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0009-0006-5646-9758</Identifier><AffiliationInfo><Affiliation>Workpartners, LLC, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghanjanasak</LastName><ForeName>Tanya</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5933-0333</Identifier><AffiliationInfo><Affiliation>Better Health Worldwide, Newfoundland, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winter</LastName><ForeName>Deborah A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0009-0001-7274-3888</Identifier><AffiliationInfo><Affiliation>Workpartners, LLC, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Feng</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9963-6863</Identifier><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escobar</LastName><ForeName>Jannette M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0009-0005-8506-1690</Identifier><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sell</LastName><ForeName>Heather</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0004-8688-3824</Identifier><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Econ</MedlineTA><NlmUniqueID>9892255</NlmUniqueID><ISSNLinking>1369-6998</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018582" MajorTopicYN="Y">Sick Leave</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007345" MajorTopicYN="N">Insurance Claim Review</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000041" MajorTopicYN="N">Absenteeism</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>COVID-19 results in short- and long-term symptoms that may affect employees&#x2019; ability to work. Short- and long-term disability (STD and LTD, respectively), other work absences, and medical and pharmacy claims from the Workpartners Research Reference Database were analyzed for US adult (&#x2265;18&#x2009;years) employees. COVID-19 claims were identified using the Center for Disease Control and Prevention recommended International Classification of Diseases codes during the analysis from 2020 to 2022. During 2020 to 2022, COVID-19 ranked as the second most frequent reason for STD claims and 13th most frequent among LTD claims. Influenza ranked 58th overall with no LTD claims (2018&#x2013;2022). The average COVID-19 STD claim lasted 24&#x2009;days and cost employers $3,477 per claim, and LTD claims averaged 153&#x2009;days, costing $19,254. Only 21.5% of employees with STD claims in the COVID-19 cohort had prior COVID-19-associated medical or pharmacy claims, and over half (range 53%&#x2013;61%) had a documented high-risk factor for severe COVID-19. Our results highlight the ongoing and substantial impact of COVID-19 on work absence benefit utilization beyond the acute phase. This analysis demonstrates the need for employers and researchers to review all available medical, pharmacy, and disability claims to assess the acute and long-term impact of COVID-19 on employees and prioritize mitigation strategies to reduce the burden of the virus to their employees.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">I10</Keyword><Keyword MajorTopicYN="N">J32</Keyword><Keyword MajorTopicYN="N">disability claims</Keyword><Keyword MajorTopicYN="N">employment</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">work absence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>18</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>10</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>10</Day><Hour>9</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38984895</ArticleId><ArticleId IdType="doi">10.1080/13696998.2024.2379056</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>